Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.
Primary Purpose
Ovarian Hyperstimulation Syndrome, Infertility Drugs, Female
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Delayed embryo transfer
Sponsored by
About this trial
This is an interventional treatment trial for Ovarian Hyperstimulation Syndrome focused on measuring GNRH agonist, ovarian hyperstimulation syndrome, Embryo cryopreservation
Eligibility Criteria
Inclusion Criteria: Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation Exclusion Criteria: Patient's refusal to participate
Sites / Locations
Outcomes
Primary Outcome Measures
Implantation rate per transfer
Pregnancy rate per embryo transfer
Implantation rate per IVF cycle
Pregnancy rate per IVF cycle
Secondary Outcome Measures
Full Information
NCT ID
NCT00365027
First Posted
August 15, 2006
Last Updated
September 3, 2015
Sponsor
HaEmek Medical Center, Israel
1. Study Identification
Unique Protocol Identification Number
NCT00365027
Brief Title
Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2015
Overall Recruitment Status
Withdrawn
Why Stopped
Enrollment difficulties
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
HaEmek Medical Center, Israel
4. Oversight
5. Study Description
Brief Summary
It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Hyperstimulation Syndrome, Infertility Drugs, Female
Keywords
GNRH agonist, ovarian hyperstimulation syndrome, Embryo cryopreservation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Delayed embryo transfer
Primary Outcome Measure Information:
Title
Implantation rate per transfer
Title
Pregnancy rate per embryo transfer
Title
Implantation rate per IVF cycle
Title
Pregnancy rate per IVF cycle
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation
Exclusion Criteria:
Patient's refusal to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eliezer Shalev
Organizational Affiliation
HaE'mek medical center
Official's Role
Study Chair
12. IPD Sharing Statement
Learn more about this trial
Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.
We'll reach out to this number within 24 hrs